PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.
X-Chem, PPD's in-house biotech company, has signed a deal with the rare disease specialists at Alexion to lend out its molecular library and help discover new treatments.
PPD has expanded its relationship with eClinical outfit Medidata, combining technologies in risk-based monitoring to help sponsors use real-time safety data to make decisions on clinical trials.
PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.
PPD is buying up the entirety of X-Chem, which operates as a biotech within a CRO, marking a vote of confidence in the continued demand for drug discovery services.
Countless clinical trials are done in by unexpectedly well-performing placebo arms, a phenomenon particularly common in psychiatric studies. PPD believes a new, proprietary trial design can substantially level the playing field, and the CRO has paid an undisclosed sum to get its hands on the technology.
PPD has signed a contract with the U.S. government's Biomedical Advanced Research and Development Authority, agreeing to design and conduct clinical trials for products that protect against bioterrorism and other public health emergencies.
PPD has signed a deal with a German hospital to help bring more clinical trials to the country, agreeing to lend its global reach and help lure drug developers.
PPD is working to get therapeutic area experts into its highest offices, poaching UCB's former head of immunology to lead its efforts in the field.
PPD has acquired Pennsylvania's Acurian, folding the company's clinical trial patient enrollment and retention services into its expanding eClinical operation.